NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Sunday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.8 %

NURO stock opened at $3.92 on Friday. The company has a market cap of $8.01 million, a PE ratio of -0.85 and a beta of 2.18. The stock has a 50-day moving average price of $4.05 and a two-hundred day moving average price of $3.84. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The firm had revenue of $0.59 million for the quarter. During the same period in the prior year, the firm earned ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.